RxDoctor Payments Data

Warren Smith, MD

Family Medicine · Boulder City, NVNPI 1679572853

Payments from drug & device makers

$3,770in general payments, 2019–2025

Across 39 payments — averaging $96.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$3K
  • Olympus America Inc.$564
  • Abbott$245
  • Astellas Pharma US Inc$87
  • Johnson & Johnson$82
  • Medtronic$75
  • plus $147 from 5 others

What the payments were for

  • Food & beverage$3,11083%
  • Education$953%
  • Other$56415%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,770 in reported general payments places this provider in the 85th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$1,150,467
Medicare patients
1,176
Services billed
74,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide206$261,211
EliquisApixaban83$119,126
JardianceEmpagliflozin76$114,557
XareltoRivaroxaban87$100,877
FarxigaDapagliflozin Propanediol44$51,936
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$47,011
Repatha SureclickEvolocumab36$37,500
RybelsusSemaglutide23$33,111
GemtesaVibegron25$30,457
MyrbetriqMirabegron25$25,307
Repatha SyringeEvolocumab31$23,567
InvokanaCanagliflozin11$18,996
JanuviaSitagliptin Phosphate14$16,441
Atorvastatin Calcium932$6,449
Breo ElliptaFluticasone/Vilanterol15$5,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invokana$82$119,87398 claims
Sumitomo Pharma America, Inc.Gemtesa$10$30,45725 claims
Astellas Pharma US IncMyrbetriq$87$25,30725 claims
AbbVieSynthroid$59$1,50922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 902 family medicine providers in Nevada.

Other family medicine in Boulder City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →